Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I perioperative intraperitoneal irinotecan plus systemic FLOT for resectable gastric or gastroesophageal junction cancer
NL-OMON58851Phase 1Recruiting
- Sponsor
- Erasmus MC
- Start
- Mar 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of irinotecan in gastric cancer (GC) and gastroesophageal junction adenocarcinoma, sponsored by Erasmus MC. Primary endpoints: Maximum tolerated dose and Recommended phase II dose. Started Mar 2026; status: recruiting.
02
Drugs
irinotecan
03
Conditions
gastric cancer (GC)gastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on NL-OMON58851.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON58851.